Literature DB >> 21545411

Translational neuropharmacology and the appropriate and effective use of animal models.

A R Green, J Gabrielsson, K C F Fone.   

Abstract

This issue of the British Journal of Pharmacology is dedicated to reviews of the major animal models used in neuropharmacology to examine drugs for both neurological and psychiatric conditions. Almost all major conditions are reviewed. In general, regulatory authorities require evidence for the efficacy of novel compounds in appropriate animal models. However, the failure of many compounds in clinical trials following clear demonstration of efficacy in animal models has called into question both the value of the models and the discovery process in general. These matters are expertly reviewed in this issue and proposals for better models outlined. In this editorial, we further suggest that more attention be made to incorporate pharmacokinetic knowledge into the studies (quantitative pharmacology). We also suggest that more attention be made to ensure that full methodological details are published and recommend that journals should be more amenable to publishing negative data. Finally, we propose that new approaches must be used in drug discovery so that preclinical studies become more reflective of the clinical situation, and studies using animal models mimic the anticipated design of studies to be performed in humans, as closely as possible.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Year:  2011        PMID: 21545411      PMCID: PMC3229750          DOI: 10.1111/j.1476-5381.2011.01361.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  17 in total

1.  Guidelines for reporting experiments involving animals: the ARRIVE guidelines.

Authors:  J C McGrath; G B Drummond; E M McLachlan; C Kilkenny; C L Wainwright
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

Review 2.  A pathophysiological paradigm for the therapy of psychiatric disease.

Authors:  Michael Spedding; Thérèse Jay; Jorge Costa e Silva; Laurent Perret
Journal:  Nat Rev Drug Discov       Date:  2005-06       Impact factor: 84.694

3.  Challenges in the search for drugs to treat central nervous system disorders.

Authors:  S J Enna; M Williams
Journal:  J Pharmacol Exp Ther       Date:  2009-01-30       Impact factor: 4.030

Review 4.  Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.

Authors:  J Gabrielsson; A R Green
Journal:  J Pharmacol Exp Ther       Date:  2009-09-24       Impact factor: 4.030

5.  Emulating multicentre clinical stroke trials: a new paradigm for studying novel interventions in experimental models of stroke.

Authors:  P M W Bath; M R Macleod; A R Green
Journal:  Int J Stroke       Date:  2009-12       Impact factor: 5.266

Review 6.  Optimising in vivo pharmacology studies--Practical PKPD considerations.

Authors:  Johan Gabrielsson; A Richard Green; Piet H Van der Graaf
Journal:  J Pharmacol Toxicol Methods       Date:  2010-02-11       Impact factor: 1.950

Review 7.  The validity of animal models of depression.

Authors:  P Willner
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 8.  Predictive validity of behavioural animal models for chronic pain.

Authors:  Odd-Geir Berge
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

9.  Stroke research at a road block: the streets from adversity should be paved with meta-analysis and good laboratory practice.

Authors:  Ulrich Dirnagl; Malcolm R Macleod
Journal:  Br J Pharmacol       Date:  2009-06-23       Impact factor: 8.739

10.  Effects of NXY-059 in experimental stroke: an individual animal meta-analysis.

Authors:  P M W Bath; L J Gray; A J G Bath; A Buchan; T Miyata; A R Green
Journal:  Br J Pharmacol       Date:  2009-04-27       Impact factor: 8.739

View more
  7 in total

Review 1.  From basic to clinical neuropharmacology: targetophilia or pharmacodynamics?

Authors:  A Richard Green; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

2.  Found in translation? Commentary on a BJP themed issue about animal models in neuropsychiatry research.

Authors:  Andrew J Lawrence; John F Cryan
Journal:  Br J Pharmacol       Date:  2014-10       Impact factor: 8.739

3.  Qualification of LSP1-2111 as a Brain Penetrant Group III Metabotropic Glutamate Receptor Orthosteric Agonist.

Authors:  Manuel Cajina; Megan Nattini; Dekun Song; Gennady Smagin; Erling B Jørgensen; Gamini Chandrasena; Christoffer Bundgaard; Dorthe Bach Toft; Xinyan Huang; Francine Acher; Dario Doller
Journal:  ACS Med Chem Lett       Date:  2013-12-12       Impact factor: 4.345

Review 4.  Lost in translation: preclinical studies on 3,4-methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans.

Authors:  A R Green; M V King; S E Shortall; K C F Fone
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 5.  An Overview of Animal Models Related to Schizophrenia.

Authors:  Ian R Winship; Serdar M Dursun; Glen B Baker; Priscila A Balista; Ludmyla Kandratavicius; Joao Paulo Maia-de-Oliveira; Jaime Hallak; John G Howland
Journal:  Can J Psychiatry       Date:  2018-05-09       Impact factor: 4.356

6.  Non-Clinical Contribution to Clinical Trials during Lead Optimization Phase.

Authors:  Lázara Martínez Muñoz
Journal:  Behav Sci (Basel)       Date:  2018-01-24

Review 7.  Translational neuropharmacology: the use of human isolated gastrointestinal tissues.

Authors:  G J Sanger; J Broad; V Kung; C H Knowles
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.